Secukinumab Bests Ustekinumab in Psoriasis CLEAR Study Save
The CLEAR study was a one-year, randomized, double-blind trial compared subcutaneous standard doses of secukinumab (anti-IL17) and ustekinumab (anti-IL12/23) in patients with moderate-severe plaque psoriasis.
Using the highest benchmark (PASI-90) as the primary endpoint, secukinumab (79.0%) was superior to ustekinumab (57.6%) at week 16. Even at the week 4 time point, secukinumab had better PASI-75 outcomes than ustekinumab (50.0% versus 20.6%). Safety outcomes were similar, there were no deaths and serious adverse events only affected 3% of each group.
Such head-to-head trials will be pivotal to patients and physicians in managing moderate to severe psoriasis.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.